Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.
4.

Formation and longevity of idarubicin-induced DNA topoisomerase II cleavable complexes in K562 human leukaemia cells.

Willmore E, Errington F, Tilby MJ, Austin CA.

Biochem Pharmacol. 2002 May 15;63(10):1807-15.

PMID:
12034365
5.

Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.

Errington F, Willmore E, Leontiou C, Tilby MJ, Austin CA.

Cancer Chemother Pharmacol. 2004 Feb;53(2):155-62. Epub 2003 Sep 23.

PMID:
14504921
6.

Curcumin induces high levels of topoisomerase I- and II-DNA complexes in K562 leukemia cells.

López-Lázaro M, Willmore E, Jobson A, Gilroy KL, Curtis H, Padget K, Austin CA.

J Nat Prod. 2007 Dec;70(12):1884-8. Epub 2007 Dec 13.

PMID:
18076140
7.

Mechanism of action of camptothecin.

Liu LF, Desai SD, Li TK, Mao Y, Sun M, Sim SP.

Ann N Y Acad Sci. 2000;922:1-10. Review.

PMID:
11193884
9.
10.

Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives.

Tanizawa A, Kohn KW, Kohlhagen G, Leteurtre F, Pommier Y.

Biochemistry. 1995 May 30;34(21):7200-6.

PMID:
7766631
11.

Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.

Chen S, Gomez SP, McCarley D, Mainwaring MG.

Cancer Chemother Pharmacol. 2002 May;49(5):347-55. Epub 2002 Mar 6.

PMID:
11976828
12.

Identification of topoisomerase I as the cytotoxic target of the protoberberine alkaloid coralyne.

Gatto B, Sanders MM, Yu C, Wu HY, Makhey D, LaVoie EJ, Liu LF.

Cancer Res. 1996 Jun 15;56(12):2795-800.

13.

Spectroscopic and biochemical characterisation of self-aggregates formed by antitumor drugs of the camptothecin family: their possible role in the unique mode of drug action.

Nabiev I, Fleury F, Kudelina I, Pommier Y, Charton F, Riou JF, Alix AJ, Manfait M.

Biochem Pharmacol. 1998 Apr 15;55(8):1163-74.

PMID:
9719470
14.

Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin.

Desai SD, Liu LF, Vazquez-Abad D, D'Arpa P.

J Biol Chem. 1997 Sep 26;272(39):24159-64.

15.

The dietary flavonoids myricetin and fisetin act as dual inhibitors of DNA topoisomerases I and II in cells.

López-Lázaro M, Willmore E, Austin CA.

Mutat Res. 2010 Feb;696(1):41-7. doi: 10.1016/j.mrgentox.2009.12.010. Epub 2009 Dec 16.

PMID:
20025993
16.

Inhibition of DNA topoisomerases I and II, and growth inhibition of human cancer cell lines by a marine microalgal polysaccharide.

Umemura K, Yanase K, Suzuki M, Okutani K, Yamori T, Andoh T.

Biochem Pharmacol. 2003 Aug 1;66(3):481-7.

PMID:
12907247
17.

Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties.

Lesueur-Ginot L, Demarquay D, Kiss R, Kasprzyk PG, Dassonneville L, Bailly C, Camara J, Lavergne O, Bigg DC.

Cancer Res. 1999 Jun 15;59(12):2939-43.

18.

DNA topoisomerase I as one of the cellular targets of certain tyrphostin derivatives.

Bendetz-Nezer S, Gazit A, Priel E.

Mol Pharmacol. 2004 Sep;66(3):627-34.

19.

Topoisomerase I-DNA complex stability induced by camptothecins and its role in drug activity.

Wadkins RM, Bearss D, Manikumar G, Wani MC, Wall ME, Von Hoff DD.

Curr Med Chem Anticancer Agents. 2004 Jul;4(4):327-34.

PMID:
15281905
20.

Detection of topoisomerase inhibitor-induced DNA strand breaks and apoptosis by the alkaline comet assay.

Godard T, Deslandes E, Sichel F, Poul JM, Gauduchon P.

Mutat Res. 2002 Sep 26;520(1-2):47-56.

PMID:
12297143

Supplemental Content

Support Center